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Abstract Identification and elucidation of the structures of
metabolites play major roles in drug discovery and in the
development of pharmaceutical compounds. These studies
are also important in toxicology or doping control with
either pharmaceuticals or illicit drugs. This review focuses
on: new analytical strategies used to identify potential
metabolites in biological matrices with and without radio-
labeled drugs; use of software for metabolite profiling;
interpretation of product spectra; profiling of reactive
metabolites; development of new approaches for generation
of metabolites; and detection of metabolites with increased
sensitivity and simplicity. Most of the new strategies
involve mass spectrometry (MS) combined with liquid
chromatography (LC).
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Introduction
Identification and structural characterization of drug metab-
olites are crucial to the drug discovery process for
optimization of metabolic stability/pharmacokinetic proper-
ties. In recent years, furthermore, increasing attention has
been devoted to drug “metabolites in safety testing”
(“MIST”) of new drugs [1–3]. It is obvious that safety
issues apply not only to therapeutic drugs but also to illicit
drugs of abuse which are often marketed without any safety
testing. These data are not only required by toxicologists
for risk assessment but also by the legislator deciding
whether such drugs should be classified as controlled
substances. Analytically, two major challenges must be
addressed. First, the metabolites must be detected, an often
challenging task, because the analytes are often present at
trace levels only in complex biomatrices, for example
biological fluids or tissues. Radiolabeled parent drugs are
often used for identification of metabolites owing to the
highly selective detection of radioactivity. Because the
synthesis of radiolabeled drugs is time-consuming and
expensive, however, this analytical approach remains
mainly limited to drug development. Second, the metabo-
lites identified must be characterized structurally. A variety
of analytical techniques have been applied, for example
MS, nuclear magnetic resonance (NMR) and infrared (IR)
spectroscopy. MS is extremely important in the identifica-
tion and characterization of metabolites of non-radiolabeled
drugs, for example those encountered in drug discovery and
in clinical and forensic toxicology.
Because gas chromatography–mass spectrometry (GC–
MS) is still widely used in clinical and forensic toxicology,
this technique is also applied to drug metabolism studies,
especially because mass spectral data is a prerequisite for
GC–MS-based general unknown screening procedures [4].
In contrast, in drug discovery and drug development LC–
MS is the technique of choice for the study of drug
metabolism. Its application is discussed in several review
papers and books [5–7]. The objective of this review is to
discuss recent progress in analytical tools used to study the
biotransformation of drugs.
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Metabolite profiling
Radiolabeled parent drug
For in-vivo and in-vitro studies of drug metabolism, use of
drugs labeled radioactively, usually with 3H or 14C
isotopes, is one of the most important tools commonly
used. LC used in combination with an on-line radioactivity
monitor (RAM) or radioactivity flow detection (RFD) is a
very common method used in studies of drug metabolism
[8, 9]. The most important advantage is that they enable
quantitation of the parent drug and its metabolites without
use of synthetic standards. The higher the level of
radioactivity, the higher the response, so analytically the
specific radioactivity should be as high as possible to
enable detection of even the lowest level of metabolites in
biological matrices. For a variety of reasons, however, e.g.
its toxicological properties, doses of radioactivity should be
kept as low as possible. Consequently, instrumentation or
analytical procedures capable of detecting low-intensity
radioactivity are needed. Chromatographic miniaturization
is highly desired for optimum signal-to-noise ratios when
using concentration-dependent detectors such as electro-
spray ionization (ESI). For several reasons, including the
smaller amounts of radioactivity injected with normal-bore
columns and the smaller peak volumes, use of conventional
on-line radiomonitors is limited because of their insufficient
sensitivity. Schultz and Alexander developed an on-column
RAM solid scintillation cell for packed LC microcolumns
(250 μm i.d.) combined with ESI–MS (LC–RAM–ESI–
MS) [10]. They showed that band broadening and RAM
sensitivity depended on the particle size of the solid
scintillant, cell volume, and cell diameter. Incorporation of
the RAM cell within the microcolumn resulted in less band
broadening than an arrangement with the RAM cell directly
connected to the end of the microcolumn. An approach
using a parallel arrangement which enabled the use of
packed capillary LC columns in HPLC–RAM–MS was
reported by Onisko [11]. Analysis was performed with a
post-column, low-dead-volume flow splitter, with a make-
up flow to increase the total flow to a value compatible with
commercially available radiochemical flow cells. Analytical
equipment using a nanosplitter interface, developed by
Andrews et al., enabled normal-bore LC (4.6 mm i.d.
analytical column at a flow rate of 1 mL min−1) to be
coupled to microelectrospray MS, which is more sensitive
[12]. A post column 9:1 split diverted 90% of the column
effluent to the radiometric detector. The nanosplitter
interface, placed further downstream, reduced the remain-
ing 10% of the flow into the MS to sub-μL min−1 levels.
This configuration enables interfacing of an analytical LC
system with RAM and MS detection under optimum
conditions for both detectors. The analytical equipment is
shown in Fig. 1. This equipment enabled detection of
metabolites of an unspecified test compound by use of a
conventional ESI interface and resulted in significant
improvement in MS sensitivity, ranging from 1.8-fold to
more than 40-fold, depending on the elution time of a given
chromatographic peak in the gradient. The major drawback
of the RFD technique is, nevertheless, the poor sensitivity
Fig. 1 Schematic diagram of an
LC–RD-MS system incorporat-
ing a nanosplitter interface.
(Reproduced from Ref. [12];
with permission)
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which results from the relatively low residence time of the
radioactive analytes in the cell at conventional LC flow
rates, which is often not sufficient for quantitation of low-
level radioactivity. As for on-line configurations, increased
counting time, resulting in improved sensitivity could be
achieved by use of stop-flow techniques. Nassar et al. used
such a stop-flow approach to study the metabolism of
unspecified [14C] labeled compounds and [3H] propranolol
[13, 14]. This on-line detection method, utilizing liquid
chromatography–accurate radioisotope counting (LC–ARC,
advanced stop-flow controller) was coupled with radioac-
tivity and MS detection. The flow from the analytical LC
column (0.45 mL min−1) was split, so that 0.10 mL min−1
was diverted to the MS and the remaining flow (0.35 mL
min−1) was diverted to a radiochemical detector together
with scintillant at a flow of 1.0 mL min−1. “By-level” stop
flow mode, which performs stop flow only on the
radioactive peaks, was used. This was a compromise,
because total run times were shorter than for use of the
“by-fraction” mode, i.e. performance of stop flow in given
count zones, but longer than for the “non-stop” mode,
which is the traditional flow-through monitor. The limit of
detection was improved by increasing the counting time
and it was found that improvement was not significant
above a counting time of 5 min. Furthermore, the ARC
flow cell/system used resulted in further improvements, for
example reduced memory effect as a result of cleaning of
the flow cells after each peak, improved background and
counting efficiency. This LC–ARC on-line stop-flow
method proved to be up to 20 times more sensitive for
detection of 14C peaks than commercially available flow-
through radioactivity detectors. Furthermore, because no
evaporation step is needed, measurement of volatile
metabolites is possible, an advantage over approaches using
fraction collection.
As an alternative to “stop flow” approaches, fraction
collection coupled with off-line radioactivity counting is
another way to increase counting time and thereby reduce
the limit of detection. LC separation, fraction collection into
test tubes, mixing with a scintillation cocktail, then off-line
liquid-scintillation counting (LSC) one fraction at a time has
become the “classic” approach for drug metabolism studies
and has traditionally been used for analysis of low-level
labeled metabolites [15]. This process is labor-intensive and
time-consuming, however. As an improvement, microplate
scintillation counting (MSC), after fraction collection into 96
well-plates, has been introduced. Two types of MSC instru-
ments are commercially available, the TopCount counter,
which uses Deep-Well LumaPlates, and the MicroBeta
counter, which uses Scintiplates [16]. After fractionation,
an evaporation step using a speed vacuum system must be
performed before radioactivity counting. Boernsen et al.
demonstrated that this approach increased throughput, by
eliminating the labor-intensive addition of a scintillant and
the long serial counting times in LSC, because the TopCount
system can count up to twelve wells at a time. It was
observed that LSC took approximately ten times longer to
count the same number of samples [17]. The combination of
analytical or narrow-bore LC and MSC (TopCount) has
already proved to be superior to on-line radioactivity
counting [18]. This approach also has another advantage.
The higher sensitivity of TopCount compared with on-line
detectors enables the use of miniaturized chromatographic
systems for MS and radioactivity detection. This also
enables much easier and more rapid peak assignment and
correlation between data from MS and radioactivity detec-
tion. Because lower sample volumes are required when
capillary LC is used, this approach even leads to a reduction
in the amount of radioactive waste.
Successful coupling of ultra-performance liquid chroma-
tography (UPLC) with TopCount has also been demon-
strated recently [19]. Zhu et al. validated TopCount with
respect to sensitivity, accuracy, precision, and radioactivity
recovery in metabolite profiling [16]. TopCount was also
shown to be 50–100-fold more sensitive than RFD and
approximately twice as sensitive as LSC. Minor metabolites
detected by TopCount were not seen by RFD, even when
four times more sample was injected. TopCount even
detected minor metabolites not detected by LSC. Analysis
of human liver microsomal incubation samples of [14C]
buspirone by use of TopCount, LSC, and RFD is compared
in Fig. 2. The accuracy and precision of TopCount were
comparable with those of RFD and precision was compa-
rable with that of LSC. Human samples, for example liver
microsomal incubations, plasma, and urine, had little or no
matrix effects on analysis of 14C isotopes, but extracts from
more than 50 mg human feces resulted in significant
quenching. Because of the fragile nature of the scintillant
bed within the well of the microplates used for the
TopCount counter, subsequent analysis of the isolated
components by MS is not possible [9] unless daughter
plates are prepared. Nedderman et al. showed that Scinti-
plates, in which the scintillant is embedded in the
polystyrene matrix of the wells, is non-destructive, i.e. the
isolated components are available for further analysis and,
therefore, metabolite identification and radiochemical quan-
titation can be achieved in a single run [9]. After
radioactivity counting, metabolites of a labeled test com-
pound could be eluted from the Scintiplates with a
methanol–water mixture, enabling mass spectrometric
characterization by infusion with an infusion pump. The
major limitation of the MSC approaches is that volatile
compounds are likely to be lost during the drying step [13,
14, 16, 17]. Zhu et al. studied the ability to detect the
volatile compound benzoic acid by use of LumaPlates and
Scintiplates, after solvent evaporation and radioactivity
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counting by use of TopCount and MicroBeta counter,
respectively [16]. Benzoic acid was completely lost in
analysis using a Scintiplates/MicroBeta counter. It could, in
contrast, be detected when LumaPlates and TopCount
counter were used. As an explanation the authors suggested
that volatile compounds may be retained on the LumaPlates
during the drying process, most probably because of
attachment to the yttrium silicate particles. Such an
attachment is very dependent on the physicochemical
properties of the metabolites and the pH of the LC solvent,
however. Loss of volatile benzoic acid was avoided when
the liquid scintillation cocktail was added directly to
Scintiplates without solvent evaporation. Borts et al. reported
a different approach for detection and characterization of the
structure of radioactively labeled compounds [20]. Similar to
the procedure described by Nedderman et al. [9], fraction
collection was performed after chromatographic separation.
These fractions were collected in “normal” 96-well plates,
aliquots of each fraction were subsequently robotically
pipetted into a second 96-well daughter plate and mixed
with liquid scintillant before radioactivity measurement and
generation of reconstructed radio-LC chromatograms. The
reconstructed radio-LC chromatogram was used for detec-
tion of metabolites. Structural characterization was per-
Fig. 2 Comparison of metabo-
lite profiles of [14C]buspirone in
human liver microsomes deter-
mined by use of LC coupled to
MSC (TopCount) (a), LSC (b),
and RFD (c), indicating the
potential of the TopCount ap-
proach for detection of minor
metabolites not detected by use
of LSC and RFD. (Reproduced
from Ref. [16]; with permission)
1368 Anal Bioanal Chem (2007) 388:1365–1380
formed by automated chip-based nanoelectrospay mass
spectrometry of the fractions of interest.
Non-radiolabeled drug
Integration of metabolite identification and characterization
into the early phase of drug discovery requires high-
throughput methods based on non-radiolabeled compounds
[5]. Staack et al. described an approach for studying the
metabolism of unlabeled drugs by on-line LC–MS–MS
combined with chip-based infusion after fraction collection
into 96-well plates [21]. A schematic diagram of the
analytical approach is shown Fig. 3. On-line MS analysis
using data-dependent acquisition combined with use of
dedicated software for metabolite detection enabled rapid
data handling for identification of metabolites. The data
obtained during the on-line MS analysis might be sufficient
for structural characterization of metabolites. If this was not
so, the data acquired on-line enabled rapid selection of
fractions of interest for subsequent re-analysis by chip-
based infusion (flow rate approximately 200 nL min−1). This
re-analysis can be performed immediately without further
sample preparation, because a pH-adjusted methanolic
solution for improved chip-based nanoelectrospray re-
sponse was added after fraction collection. Owing to
reduced sample consumption, typically 1 to 5 μL, together
with the use of multiple channel acquisition (MCA), and
the ability to infuse the sample for an extended period of
time, acquisition time was no longer an issue, which
resulted in improved quality of the MS–MS spectra and
increased sensitivity. The MS experiments required for
structure elucidation, e.g. neutral loss (NL), enhanced
product ion (EPI), MSn, can be performed during infusion
and the same fraction can even be analyzed on different
MS instruments if, for example, other specific MS features
are needed. Another advantage is that the eluent can easily
be optimized for other infusion experiments, e.g. when
polarity switching is required or for H–D exchange
experiments. Thus, besides the gain in data quality, this
concept proved to be time-saving, because no time and
labor-intensive re-injections or sample pre-concentration
steps were needed. Consequently, because fewer re-
injections are needed, even flat generic LC gradients
which enable good chromatographic separation can be
used without compromising throughput.
Chip-based nanoelectrospray has also proved suitable for
the analysis of glutathione (GSH) adducts. In a study
performed with authentic standards of GSH adducts, chip-
based nanoelectrospray was shown to be 100 times more
sensitive than conventional LC–MS–MS [22]. Yu et al.
used automated chip-based nanoelectrospray for a sensitive
screening for GSH adducts of diclofenac and detected a
previously unreported diclofenac–GSH adduct [23]. The
MS analysis was performed off-line with no HPLC
separation. After quenching of the microsomal incubations
with methanol, the supernatant was evaporated to dryness,
reconstituted (5% MeOH in 1% HCl) and extracted using
an HLB μElution plate. A neutral loss (NL) scan of 129
was used for detection of GSH adducts and MS–MS spectra
were then recorded for structure elucidation.
Use of matrix-assisted laser desorption/ionization (MALDI)
techniques is an alternative to nanoelectrospray analysis.
Hopfgartner et al. used a parallel nano-LC column switching
system with post column addition of the MALDI matrix so-
lution before fraction collection on MALDI plates for analysis
of metabolites of vinpocetine formed in rat microsomal incu-
bations. The collected fractions were subsequently analyzed by
use of an orthogonal MALDI (oMALDI) QqTOF instrument.
Use of this approach yielded the same results as the approach of
fraction collection/chip based nanoelectrospray analysis [24].
Fig. 3 Schematic diagram of
the configuration of on-line
LC–MS with fraction collection
and off-line chip-based infusion.
(Reproduced from Ref. [21],
with permission)
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Predictive and non-predictive metabolite profiling
software
Over the last few years much effort has been devoted to
developing in-silico tools for prediction of adsorption,
distribution, metabolism, and excretion (ADME). For drug
metabolism two major questions must be answered:
1. how and into what metabolite will the drug be trans-
formed? and
2. what relative amount of the metabolite will be
produced?
Metabolism occurs through many different well-charac-
terized enzymes and new metabolic routes can be combined
to form databases. Today, a variety of expert systems are
available for prediction of metabolic events. The remaining
challenge is to prioritize the important ones. The molecular
characteristics of the metabolites can be used by the analyst
to perform target-based mass spectrometric profiling. Anari
et al. [25, 26] integrated knowledge based prediction with
LC–MS–MS to study the biotransformation of indinavir.
Prediction of the metabolites enables the setting of a variety
of data-dependent experiments using inclusion lists. Using
this approach they were able to detect eighteen metabolites
of indinavir in human microsomes in one LC–MS–MS
analysis.
Most commercial mass spectrometers have software
which enables metabolite profiling. Hakala et al. [27] have
investigated the potential of a quadrupole-time-of flight and
triple quadrupole instruments, with their corresponding
proprietary software, for automated metabolite profiling of
tramadol in human urine. They reported that, despite the
time saving, none of the systems was able to detect low
levels of unexpected metabolites in urine. Also, to avoid
false positives, all hits had to be validated manually. This
example shows clearly the limitation of software approaches
for metabolite profiling. It appears from experiments to date
that most of the software tools are not smart enough to
automate manual approaches with equivalent information.
Therefore, improvement in such software is expected.
Interpretation of product-ion spectra
Collision-induced dissociation (CID) provides structurally
informative spectra either in the source region of an
atmospheric-pressure interface or by tandem mass spec-
trometry (MS–MS). The product ion spectra are usually
obtained either in trap CID or in quadrupole CID mode and
the spectral features are very dependent on the instrument
and the tuning parameters. Use of hybrid instruments, for
example a quadrupole time-of-flight or a two dimensional
ion trap coupled either to Fourier-transform MS or an
Orbitrap also enable accurate measurement of the frag-
ments. For identification of unknown compounds, search-
able MS–MS libraries are very attractive. Although the
electron-impact (EI) library of the NIST 05 mass spectral
database contains 163,198 unique compounds, the MS–MS
library contains 1,943 different entries only (positive and
negative ion mode). The NIST 05 EI library is often far too
large and smaller more accurate libraries are used for
toxicological or metabolic investigations [28]. Several
groups [29–34] have investigated different conditions
affecting MS–MS spectral search, for example instrument
type (ion trap or triple quadrupole) or collision energy and
suggest that library searches are sufficiently efficient for
identification of unknown compounds from product-ion
spectra. However, it has to be noted that most of the work
was performed on small libraries which also do not
consider accurate mass measurements [35] or the isotopic
distribution of the precursor ion. We believe more inves-
tigations will have to be performed before it becomes
possible to achieve reliable LC–MS–MS identification of
unknown compounds in complex biological matrices by
use of large libraries such as reference MS–MS spectra of
pharmaceuticals, illicit drugs, and endogenous metabolites.
In studies of drug metabolism the structure of the parent
drug is usually known. Interpretation of the MS–MS
spectra of metabolites is then mainly performed compara-
tively by using knowledge of the fragmentation cascade of
the parent drug [36, 37]. As an example, a shift of 16
Daltons (Da) from a known fragment of the parent will
enable the analyst to locate the region of the molecule
which was hydroxylated. On the basis of the chemical
structure of compounds, fragmentation rules have been
developed which enable automated interpretation of spec-
tra. The two software packages most often used are Mass
Frontier [38] (HighChem) and MS Fragmenter [39]
(ACDLabs). The products usually assume fragments are
even-electron ions and apply known fragmentation rules;
usually, therefore, they have difficulties assigning complex
rearrangements or odd-electron fragments, which occur
more often than expected [40]. With Mass Frontier the user
can either select common fragmentation rules and/or search
in a library. Sweeny [41] has described an approach based
on the concept that a molecule can be represented as a sum
of unbreakable cells of known elemental composition
connected by cleavable bonds. He made three assumptions:
1. the fragments are even-electron ions;
2. no re-arrangements occur; and
3. the simplest solution of a spectrum is the most likely.
Using these assumptions he developed a software based
on a mathematical partitioning algorithm which converts
spectral data into a modular structure and demonstrated the
feasibility of the approach with several examples. Hill et al.
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[42] developed an alternative approach based on high-
resolution CID mass spectra using a systematic bond-
disconnection approach. The process starts with the
structure of the precursor and the software disconnects all
possible substructures of n bonds. In a second step, all
possible elemental formulas for the substructures are
generated and both results are matched using double-
equivalent-bond and electron-parity filters. Despite these
efforts, automated interpretation of spectra remains chal-
lenging and will require further improvements of existing
approaches. It has, however, become evident that whatever
the software used accurate-mass product-ion spectra greatly
reduce the number of fragment structures possible.
MS does not enable full structure characterization, as is
possible with NMR. Often, however, insufficient material
or time is available to perform such analysis and one must
rely on MS alone. A simple way of increasing the amount
of structural information is to perform deuterium exchange
experiments or chemical derivatization. Chemical derivati-
zation of low-molecular-weight compounds has been used
for many years to improve the detection or chromatograph-
ic behavior of pharmaceutical compounds. Liu and Hop
[43] have reviewed the use of derivatization agents in LC–
MS–MS. Incubation of pioglitazone in dog microsomes
generates two isobaric hydroxylated metabolites (M4 and
M7). The product-ion spectra indicate the location of
hydroxylation but do not enable differentiation between
the terminal hydroxyl form and the ω-1-hydroxy form. The
complete sample was oxidized using the Jones reagent. One
of the metabolites (M4) gave the ketone metabolite (ω-
1-hydroxy form) whereas the other (M7) gave the carboxylic
acid (terminal hydroxy form). In this instance complete
elucidation of the structures of the two metabolites was
possible by mass spectrometry only.
Reactive metabolite profiling
In 1994 over two million hospitalized patients had serious
adverse drug reactions and for 106,000 the outcome was
fatal. Adverse drug reactions are believed a leading cause of
death in the United States, emphasizing the huge importance
of this issue to the pharmaceutical industry [44]. The
emergence of idiosyncratic toxicity resulting in the with-
drawal of a new drug from the market can be regarded as
the worst case scenario for a pharmaceutical company [45].
A high proportion of drugs involved in idiosyncratic
toxicity are capable of forming reactive metabolites [5, 6].
Bioactivation can result in the formation of electrophilic
and/or free radical metabolites which are thought to cause
toxicity by covalently altering cellular macromolecules
such as proteins or DNA [45–47]. These reactive metabo-
lites can be generated by metabolic phase-I reactions
(oxidation, reduction), e.g. catalyzed by cytochrome
P450s (CYP), flavin monooxygenases (FMO), and perox-
idases, for example as myeloperoxidase (MPO) and cyclo-
oxygenases (COX), and also by phase-II reactions
(conjugation), e.g. catalyzed by UDP glucuronyltrans-
ferases (UGT) or sulfotransferases (SULT) [46]. According
to the “hapten hypothesis” for idiosyncratic drug reactions,
a chemically reactive drug or a reactive metabolite
covalently binds to protein. These adducts are immunogen-
ic and can trigger immune responses, leading to idiosyn-
cratic drug reactions [45, 48]. The many examples of drugs
that have been reported to form reactive metabolites and
cause hepatotoxicity or idiosyncratic toxicity suggest a
possible role in the mechanism of such toxicity. A role in
causality in disease has not been demonstrated, however,
and there are examples of drugs that form reactive
metabolites but cause no apparent toxic effects. Several
other variables, for example dosage, usage, detoxification
of reactive metabolites, and the existence of multiple
metabolic pathways, have an affect on whether a drug
known to undergo bioactivation to a reactive metabolites
will cause toxicity [45–50]. On the basis of the possible
correlation between reactive metabolites and idiosyncratic
drug reactions, formation of a large amount of reactive
metabolites is regarded as significant liability for a drug
candidate. Screening for such metabolites has become part
of the early stages of the drug-development process.
Identification of such candidates enables prioritization of
drug candidates, e.g. before radiolabeling for covalent
binding assays. It also provides data for rational changes
in structure by the medicinal chemist to minimize this
process [46, 50].
The reactive metabolites, usually electrophiles, are
usually, hydrophilic, formed in small quantities, and
extremely short-lived and so are not usually detectable in
plasma [49]. Stable, downstream metabolites, e.g. mercap-
turic acid conjugates resulting from glutathione conjugation
of reactive intermediates, may be detected in excreta and
serve as an indication of exposure to these reactive
metabolites [1, 2]. Thus, because direct detection and
characterization of reactive metabolites in biological sys-
tems is extremely challenging, the strategy of trapping these
intermediates in situ and in in-vitro assays is widely used.
Analysis and assessment of the toxicity of reactive
metabolites have been the subject of numerous reviews
[46, 48, 50–54]. The focus here is on novel analytical
approaches for detection of these metabolites.
In vitro trapping in situ
Because of to the short lifetimes of electrophilic reactive
intermediates, the strategy of trapping these intermediates in
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situ is widely used. The in-vitro assay most widely used to
screen for reactive metabolites is liver microsomes supple-
mented with a NADPH/NADPH regenerating system, as co-
factor for CYP 450-catalyzed reactions, and a “trapping
agent”. Although CYP 450 enzymes are important in gen-
erating reactive metabolites, other bioactivation pathways
should be kept in mind when choosing the in-vitro test system,
i.e. addition of different co-factors, use of different in-vitro
systems, for example hepatocytes or neutrophils [48, 49,
55, 56]. Different nucleophiles are used as trapping agents, for
example thiols (e.g. glutathione (GSH) and N-acetylcysteine),
amines (for example semicarbazide and methoxylamine), and
cyanide anions. “Soft nucleophiles” usually tend to react with
“soft electrophiles” and “hard nucleophiles” tend to react
with “hard electrophiles”. The most widely used trapping
agent GSH, a soft nucleophile, has been shown to react with
quinoneimines, nitrenium ions, arene oxides, quinones, imine
methides, and Michael acceptors [50]. Hard electrophiles, for
example iminium species or aldehydes and ketones, will react
with cyanide or amines, respectively [56–59]. The adducts
formed can subsequently be characterized for structure
elucidation and quantification.
Glutathione adducts
The use of [3H]-labeled GSH was reported by Thompson
et al. several years ago and is still in use [16, 60]. Hartman
et al. developed a hepatocyte-based glutathione assay with
intracellular generation of radiolabeled GSH [61]. For this
purpose, hepatocytes were incubated in methionine and
cystine-free (“thiol-free”) medium before exposure to 35S-
labeled methionine, which results in augmentation of the
cellular GSH pool with intracellularly generated 35S-labeled
GSH. In recent years several new, mainly LC–MS based,
approaches have been reported which do not use radio-
labeled GSH. The purpose of these new analytical ap-
proaches, using innovative detection techniques or new
trapping assays, was to improve sensitivity, selectivity, and
throughput in screening for reactive metabolites.
The detection of “minor” GSH conjugates is also an
important issue. The abundance of GSH conjugates formed
in microsomal incubations is determined by several factors,
for example the CYP enzyme content, the concentration of
the substrate, the extent of bioactivation, and the trapping
efficiency of GSH, and the amounts of adducts formed are
not necessarily proportional to the amounts of the
corresponding reactive metabolite. This is especially true
for the highly reactive metabolites, which tend to react with
microsomal proteins, for example, and so fewer molecules
are trapped by GSH. High substrate concentrations were
usually used to generate adequate conjugate concentrations
for detection. GSH conjugates, when fragmented under
CID conditions, give a characteristic loss corresponding to
the pyroglutamic acid (129 Da) moiety [62]. Hence,
constant neutral loss scanning for 129 Da is traditionally
the most widely used MS–MS survey scan for screening for
GSH conjugates. Triple-quadrupole instruments have most-
ly been used for these analyses, using neutral loss scan with
nominal mass. Poor sensitivity resulting from the low
abundance of precursor ions and the fact there is no
optimum collision energy for all GSH adducts are the major
drawbacks of this approach [63]. Poor selectivity is also an
issue. Not only GSH conjugates but also endogenous
compounds may lose 129 Da. This fragment loss has the
same nominal mass but is not a GSH fragment, which
yields false-positive results. To exclude these false pos-
itives, Castro-Perez et al. developed a screening procedure
using exact mass measurement and MS–MS on a hybrid
quadrupole time-of-flight (TOF) mass spectrometer [64].
The instrument acquired survey mass spectra in MS mode
with the quadrupole operated in wide band-pass mode.
Alternate low and high-energy spectra were generated in
positive-ion mode by switching the collision energy
between 5 and 20 eV and the system was set to examine,
in real time, consecutive pairs of low and high-energy
spectra for ions separated by 129.0426 Da, the exact mass
of pyroglutamic acid, within a window of ±20 mDa.
Whenever this exact neutral loss was detected the instru-
ment automatically switched to MS–MS mode. This exact
mass neutral loss acquisition enabled extremely selective
detection and identification of GSH conjugates with
reduced numbers of false positives, because only “real
GSH conjugates” were detected.
A fundamental problem of using a constant neutral loss
scan atm/z 129 is that this neutral loss is not observed for all
classes of GSH adduct under CID conditions, for example
aliphatic and benzylic thioethers—elimination of GSH ([M+
H]+−307 (as a neutral) [M+H]+−308 (as GSHþ2 ))—and
thioester conjugates—loss of glutamic acid and water ([M+
H]+−147) [62, 65]—and consequently escape detection.
Another problem is the formation of doubly charged
[M+2H]2+ ions of GSH adducts, for which neutral losses
are not observed as a typical fragmentation pattern.
Dieckhaus et al. demonstrated that a precursor ion scan of
m/z 272 in negative-ion mode enables broader screening for
unknown GSH conjugates belonging to different structural
classes [66]. Under negative-ion conditions CID of GSH
and all major classes of GSH conjugates afforded a com-
mon fragment ion at m/z 272 (elimination of H2S, de-
protonated glutamyldehydroalanylglycine). Figure 4 shows
results from LC–MS–MS analysis of model GSH adducts
using positive-ion neutral-loss scan of 307 Da (panel A),
positive-ion neutral-loss scan of 129 Da (panel B), positive-
ion precursor scan of m/z 130 (panel C), and negative-ion
precursor scan of m/z 272 (panel D). Only scanning for
precursors of m/z 272 in negative-ion mode enabled
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detection of all adducts in a single run. A possible increase
in sensitivity of detection could, furthermore, be assumed,
because in negative-ion mode multiply-charged anions are,
typically, not found. Thus an increased number of singly-
charged ions would be present. The potential of this
approach was demonstrated by analysis of in-vivo and
in-vitro samples of compounds known to form GSH adducts.
The procedure always revealed the presence of the expected
adducts and even previously unreported conjugates were
detected. A disadvantage of the method lies in that the MS/
MS spectra of GSH adducts acquired in negative mode
showed almost exclusively fragments of the GSH moiety
and provided only limited structural information of the
trapped metabolite. The combination of precursor ion
scanning of m/z 272 in the negative-ion mode as survey
scan, combined with polarity switching and product-ion
scanning as the dependent scan in positive-ion mode was
proposed by the authors as a strategy that would enable
selective screening for GSH adducts in combination with
full-scan product-ion spectra of the MH+ ion for structure
elucidation.
Use of stable-isotope-labeled GSH as a trapping agent
for high-throughput screening of reactive metabolites with
enhanced sensitivity and selectivity has been reported by
different groups [63, 67–69]. Mutlib et al. used stable
isotope-labeled GSH (deuterium-labeled in the glutamate
moiety) to demonstrate transfer of glutamate from GSH to
benzylamine derivatives in the presence of γ-glutamyl-
transpeptidase, and proposed use of 1:1 mixtures of
labeled and unlabeled GSH for study of reactive
metabolites [69]. In later studies 1:1 mixtures of unlabeled
GSH and GSH labeled with 13C2–
15N in the glycine moiety
was used for trapping reactive metabolites in microsomal
incubations [63, 67, 68]. As illustrated in Fig. 5, the idea of
this concept is that both labeled and unlabeled GSH
conjugates undergo the same neutral loss of pyroglutamic
acid (129 Da) by CID fragmentation. As a result, constant
neutral loss MS–MS spectra contain an isotopic doublet of
the same intensity that differs in mass by 3 Da, a mass
difference between a compound and its metabolites which
is very uncommon.
A wide variety of model compounds known for GSH
adduct formation chosen to represent the diversity of
molecular structures and bioactivation pathways were
analyzed as positive controls; compounds known not to
form reactive metabolites were used as a negative control.
The results were consistent with those reported in the
literature, demonstrating the procedure is a highly reliable
means of detection of reactive metabolites. Novel reactive
metabolites could also be identified [67, 68].
The stable-isotope trapping procedures described did not
enhance the signal-to-noise ratio in either the total-ion
chromatogram or the neutral-loss scan. The unique isotopic
doublet is easily recognized visually even at low signal-
Fig. 4 Results from LC–MS–MS analysis of model GSH adducts by
positive-ion neutral-loss scanning of 307 Da (a), positive-ion neutral-
loss scanning of 129 Da (b), positive-ion precursor scanning of m/z
130 (c), and negative-ion precursor scanning of m/z 272 (d), indicating
that only scanning for precursors of m/z 272 in negative-ion mode
enabled detection of all the adducts (γ-glutamyl-S-(1-[4-(dimethyla-
mino)phenyl]-3-hydroxypropyl)cysteinylglycine (DACA-GSH), γ-
glutamyl-S-[2,6-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidin-4-yl]
cysteinylglycine (TNP-GSH), γ-glutamyl-S-[2-hydroxy-1-(2-hydrox-
yethyl)heptyl]cysteinylglycine (4-HNE-GSH), and diclofenac-S-acyl-
GSH (D-GSH)) in a single run. (Reproduced from Ref. [66]: with
permission)
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to-noise ratios. This explains why GSH adducts can be
detected reliably at low levels, even though the signal was
diluted twofold as a result of the use of a 1:1 mixture of
labeled and unlabeled GSH. This high sensitivity enabled
microsomal incubations at low concentrations, avoiding
solubility problems or CYP inhibition. The feasibility of
the method for completely automated detection by comput-
er-assisted pattern recognition was also demonstrated [68].
Mutlib et al. performed stable-isotope labeling and
analyzed the samples on two different linear ion-trap MS
instruments (LTQ linear ion trap, Thermo Electron, and
4000 QTrap linear ion trap, Applied Biosystems). They
found the results were comparable and that in both cases
the relevant data could be acquired in a single analysis [63].
Because of fundamental differences between the two
instruments, different strategies were necessary to acquire
the data. Data-dependent acquisition using full-scan mode
with MS–MS and MS3 was used on the LTQ linear ion trap.
Because “traditional” neutral-loss scanning was not possi-
ble with this instrument, “neutral-loss ion maps” were
obtained retrospectively from the MS–MS data. With the
4000 Qtrap linear ion trap, data-dependent acquisition was
performed using neutral-loss scans as the survey scan and
MS–MS and MS3 as dependent scans.
Soglia et al. used a different approach to address the
limitation of low sensitivity. The objective was to optimize
both the in-vitro test method and LC–MS–MS analysis.
Instead of GSH the close analog glutathione ethyl ester
(GSH-EE) was used as trapping agent and the microsomal
incubations were analyzed after semi-automated 96-well
plate solid-phase extraction using microbore liquid chro-
matography–micro-electrospray ionization–tandem mass
spectrometry (μLC–μ-ESI-MS–MS) [70]. Twelve test
compounds were analyzed using GSH and GSH-EE as
trapping agents. Use of GSH-EE improved the detection
capability of the assay almost threefold (conjugates were
detected for four out of twelve test compounds (33%) by
use of GSH and ten out of twelve using GSH-EE). By using
p-nitrophenyl GSH and GSH-EE conjugates as standards, a
tenfold increase in slope, which equates to a tenfold
increase in MS sensitivity, and reduced limits of detection
(3 nmol L−1 compared with 0.34 nmol L−1) were also
obtained. An increase in sensitivity of detection of the
GSH-EE conjugates compared with the GSH conjugates
was also observed for each of the compounds tested, with a
peak-area increase of approximately eightyfold for acet-
aminophene–GSH-EE. Apart from the increased MS
detection sensitivity for GSH-EE conjugates another factor
might explain to this observation. The ethyl ester moiety in
GSH-EE makes the molecule less polar than GSH, which
resulted in an increase in the retention time of the
conjugates during reversed phase chromatography and
would explain the higher SPE recovery.
Other GSH derivatives were tested with regard to
obtaining additional quantitative data. Gan et al. developed
a quantitative method using a dansylated GSH derivative,
with the fluorescent dansyl group being added to the free
amino group of GSH [71]. With 1-chloro-2,4-dinitroben-
zene and R-(+)-pulegone as test compounds dansyl GSH
was found to be equivalent to GSH in chemical reactivity.
Danysl GSH adduct formation was demonstrated for seven
test compounds known to form GSH conjugates whereas no
such adducts were detected after microsomal incubations
with test compounds chosen as negative controls, i.e. for
which no GSH adduct formation had been described in the
literature. It was also shown that, because of the introduc-
Fig. 5 Schematic diagram of
the strategy for stable-isotope
trapping and constant neutral-
loss scan analysis for detection
of reactive metabolites. (Repro-
duced from Ref. [68]; with
permission)
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tion of the bulky dansyl group, dansyl GSH did not serve as
a cofactor for glutathione S-transferase (GST) and no CYP
450 inhibition was observed. The LC system was coupled
in series with a fluorescence detector for quantitation, along
with an MS system. Because fluorescence detection is used
for quantitation, adequate chromatographic separation of
the dansyl GSH adducts from unreacted dansyl GSH is
required, however; this results in long LC methods (total
analysis time 50 min), which limits its application as a
high-throughput method.
Soglia et al. proposed use of a quaternary ammonium GSH
analog (QA-GSH, bearing an N-methylethylpiperidinium
moiety on the C terminus of the glutamate portion of GSH)
for semi-quantitative LC–MS–MS determination of reactive
metabolites. Comparison of equimolar amounts of the parent
standards and the corresponding QA-GSH standards showed
that conjugation with QA-GSH resulted in improved
detection capability and equal MS response. The MS signal
responses of the QA-GSH conjugate reference compounds
were within a factor of 3.3 of each other whereas the
responses of the corresponding parent standard differed by as
much as nineteenfold. Because the MS response is,
obviously, predominantly based on the fixed charge of the
QA-GSH moiety, one might assume that conjugation of QA-
GSH with other compounds should result in similar MS
responses. Furthermore, only a 1.5-fold difference in slope of
the standard curves of QA-GSH standards was observed.
For semi-quantitative analysis QA-GSH internal stand-
ards (one singly charged and one doubly charged) were
added to the microsomal incubation sample before analysis.
LC–MS–MS analysis was performed using capillary LC
coupled to microelectrospray ionization–tandem mass spec-
trometry. In the first step the QA-GSH conjugate of interest
must be identified. This was achieved either by calculation of
m/z for the M+ and MH2+ ions of the QA-GSH conjugate of
interest for multiple single reacting monitoring analysis or
by precursor-ion scanning of m/z 144 (corresponding to the
4-hydroxy-N-methylethylpiperidinium ion). When m/z for
the M+ or MH2+ ion had been verified an MS method was
used to monitor four independent scan events (MH2+ and
M+ of the QA-GSH adduct of interest and the MH2+ and
M+ for the internal standards) during semiquantitative LC–
MS–MS analysis. A response factor, i.e. peak area/
concentration was calculated for the internal standards.
Semi-quantitative analysis was performed by dividing the
peak area of the QA-GSH conjugate of interest by the
response factor of the internal standard with the same
charge state, i.e. M+ or MH2+.
Cyanide adducts
During metabolic activation hard electrophilic metabolites
are also generated, e.g. iminium ions are derived from
compounds with an alicyclic amine structure. Cyanide, a
hard nucleophile, has also been used as trapping agent for
detection of this kind of reactive metabolite. The comple-
mentary nature of both trapping methods (i.e. using GSH
and cyanide) for screening has been demonstrated for
several compounds [72]. Gorrod et al. described the use of
radiolabeled [14C]cyanide several years ago [59]. Meneses-
Lorente et al. extended this approach to semiautomated
high-throughput analysis [73]. After incubation of cold test
compounds with liver microsomes in the presence of [14C]
cyanide the unreacted trapping agent was removed by solid
phase extraction and the amount of radiolabeled conjugate
was determined by liquid scintillation counting. Evans et al.
mentioned use of a 1:1 mixture of cyanide and stable
isotopically labeled cyanide (13C15N−). They reported that
detection of the adducts was greatly facilitated by the
presence of prominent isotopic doublets, which differed in
mass by 2 Da (mono adduct) or 4 Da (bis adduct) and that
the MS–MS spectra were characterized by neutral loss of
27/29 (CN−/13C15N−) [50]. Argoti et al. developed an LC–
MS–MS method for screening iminium ion formation in
liver microsomes using cyanide [72]. The microsomal
incubation mixtures were fortified with KCN or K13C15N.
Screening for the cyanide conjugates was by constant
neutral loss scanning of 27 (CN−) or 29 (13C15N−).
Fourteen alicyclic amine compounds were investigated
with the cyanide trapping screen and also with the GSH
trapping screen. Comparison of the results revealed the
importance of cyanide trapping for detection and identifi-
cation of iminium ion intermediates and the complementary
nature of GSH and cyanide trapping experiments.
Other peptides
Reichardt et al. proposed a model using a dipeptide for
monitoring adduct formation of xenobiotics and for
characterization of molecular structures [74]. Lysine–tyro-
sine (Lys–Tyr) was chosen as model peptide. A dipeptide
was chosen to minimize steric hindrance and dipole effects,
factors that are known to affect the characteristics of
binding to proteins. Lysine was chosen because of its high
basicity and degree of ionization—the ɛ-amino group of
lysine is among the most characteristic groups commonly
involved in protein–xenobiotic interactions in vivo. Tyro-
sine was chosen as a second amino acid because its
aromatic ring is readily detectable in UV light and because
of its much lower reactivity, which favors reaction at the
lysine residue. Test compounds, including aldehydes and
other electrophilic compounds, were incubated with the
dipeptide at 37 °C and pH 7.4 (phosphate buffer). After
centrifugation the adducts were analyzed by flow-injection
analysis MS (FIA–MS). Besides adduct formation with
aldehyde groups by formation of Schiff bases, the covalent
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adducts of other electrophilic compounds, for example
toluene-2,4-diisocyanate, 2,4-dinitro-1-fluorobenzene,
2,4,6-trinitrobenzene sulfonic acid, dansyl chloride, and
phthalic acid anhydride, could also be detected with the
lysine moiety. Quantitation of peptide reactivity was
performed by the determination of the amount of peptide
with unchanged molecular structure remaining following a
specific time of incubation by HPLC-UV in combination
with fluorescence monitoring. A factor of reactivity defined
as the amount of xenobiotic necessary to enable reaction
with 50% of the peptide in a given solution, was calculated
and used.
Wang et al. used a slightly different dipeptide, lysine–
phenylalanine (Lys–Phe), to study the reactivity of acyl
glucuronides to proteins [75]. Acylglucuronides are formed
as major metabolites of most compounds with a carboxylic
acid moiety. Although, acylglucuronides are reactive
electrophiles they are relatively stable compared with other
reactive metabolites and can circulate in the body and are
excreted in the urine or bile [76]. Their chemical reactivity
is suspected of being responsible for the toxicity of
carboxylic acids. Covalent binding to proteins may occur
by two different mechanisms [77], by transacylation, i.e.
nucleophilic attack of the acyl carbon of the glucuronide,
by a nucleophilic group of a protein, resulting in liberation
of the glucuronic acid and acylated protein, or by glycation.
After acyl migration the resulting positional isomers can
exist transiently in the open-chain form of the sugar ring,
thereby exposing the aldehyde group, which can form a
Schiff base, e.g. with the ɛ-amine group of a lysine residue
of a protein. In this case, the glucuronic acid moiety is
retained in the adduct, forming a bridge between the
aglycone and the target protein.
The purpose of the approach of Wang et al. was to
determine the reactivity of acylglucuronides toward the test
peptide, by monitoring the formation of adducts by the
Schiff base mechanism. The procedure included two
incubation steps—first, formation of acylglucuronides by
incubation of the carboxylic acid-containing compound
with human liver microsomes fortified with uridine diphos-
phate glucuronic acid (UDPGA), and, second, formation of
adducts by addition of the model peptide to the supernatant
of the first-step incubation. After dilution of an aliquot with
50:50 methanol–water the samples were analyzed by LC–
MS.
Cobalamin
Analysis of low-molecular-weight, highly reactive hydro-
philic compounds, for example epoxy metabolites of 1,3-
butadiene is particularly difficult. Although GC has been
used for analysis after solvent or head-space extraction,
neither procedure is optimum for hydrophilic low-molecu-
lar-weight compounds. The supernucleophile cob(I)alamin,
a highly nucleophilic compound, has been proposed as an
analytical tool for characterization of reactive metabolites.
When cobalamin (Co(III)) is reduced to cob(I)alamin, the
upper ligand is replaced by a free pair of electrons, which
react rapidly with electrophilic compounds, for example
oxiranes, to form alkyl cobalamin complexes [78]. These
polar alkyl cobalamin complexes of high molecular weight
are amenable for analysis by LC–MS. Haglund et al.
developed a validated capillary LC–ESI-MS–MS method
using multiple reaction monitoring (MRM) mode with
column switching for sensitive and accurate determination
of reactive metabolites trapped with cob(I)alamin [79]. The
power of this approach was demonstrated by using die-
poxybutane, a metabolite of 1,3-butadiene (MW 86.1 Da),
as test compound. The intermediate metabolite epoxybu-
tene was incubated with S9 fraction fortified with NADPH
for CYP450-catalyzed bioactivation to diepoxybutane.
Aliquots of the incubation sample were mixed with cob(I)
alamin solution before analysis of the alkyl cobalamin
complexes formed.
New approaches for metabolite generation
On-line metabolism with immobilized enzyme
reactors–chip MS
Traditionally, in-vitro test methods (e.g. liver microsomes,
cytosol or S9 fractions, cell lines, primary hepatocytes, liver
slices, and perfused livers) are used for drug metabolism
studies in early drug discovery [55]. Incubations with these
in-vitro systems are performed “off-line”, with subsequent
analysis of the metabolites formed. Several approaches
using methods for “on-line metabolite generation” have
been described to increase throughput in early drug-
metabolism studies. Production of immobilized enzyme
reactors (IMERs) is a well known approach which enables
on-line coupling of enzyme-catalyzed reactions with LC
[80]. This method has also been used in the field of drug
metabolism. Monoamine oxidase A and B IMERs have
been developed by non-covalent immobilization of human
MAO A and B on an immobilized artificial membrane
(IAM) stationary phase and coupled on-line with LC–UV
[81]. The same group also reported the on-line coupling of
a uridine diphosphoglucuronyltransferase (UDPGT)-IMER
with HPLC–UV [82]. The UDPGT-IMER was prepared by
covalent immobilization of nonsolubilized rat liver micro-
somal UDPGT on an activated diol-bonded silica LC
support. Column-switching was performed with a mixed-
mode C18–anion-exchange column as trapping column and
a C18 analytical column. Use of the mixed-mode trapping
column enabled the retention of the parent compound and
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the formed glucuronides which differ substantially in
polarity. Capillary electrophoresis (CE) can also be used
for on-line glucuronidation studies. On-column immobili-
zation of microsomal UDPGT has been described by Sakai-
Kato et al. [83, 84] and Kim and Wainer [85]. Different
analytical approaches have been described for on-line
coupling of cytochrome P450-catalyzed reactions. Pulsed
ultrafiltration–mass spectrometry (PUF–MS) has been
performed after incubations with liver microsomes trapped
in an ultrafiltration cell to which the substrates and
cofactors had been added by flow injection. A methylcel-
lulose ultrafiltration membrane enabled elution of the low-
molecular-weight metabolites formed. The sample could be
analyzed by on-line ESI–MS or the analytes could be
trapped on an LC column before analysis by LC–MS.
Application of this technique in drug-metabolism studies
has been reviewed by Johnson et al. [86].
Micosomal incubations in a chip-based format coupled
to ESI-MS has been demonstrated by Benetton et al. [87].
The chips used were made of a cyclic olefin polymer. Two
syringe pumps delivered microsomal protein, in an appro-
priate buffer, and a mixture of the substrate and cofactors to
the reaction region (volume 4 μL) of the chip, where
incubation at 37 °C was performed. Two different config-
urations were used for desalting, removal of proteins. and
preconcentration before MS analysis. First, an off-chip
guard column was used. Second, a porous monolithic
column was integrated into the chip which enabled fully
integrated on-chip sample preparation.
Electrochemical generation of metabolites
A purely instrumental approach is the use of on-line
electrochemistry–mass spectrometry (EC–MS) to mimic
cytochrome P450-catalyzed reactions. Application of EC–
MS in drug metabolism has been reviewed by Karst [88].
Coupling of electrochemistry to liquid chromatography–
mass spectrometry (EC–LC–MS) has recently been
reported. This analytical configuration enabled generation
of more data on the oxidation products, e.g. information
on the polarity of the oxidation products or the potential
to detect the formation of isomers of metabolites [89,
90].
EC–MS and EC–LC–MS studies on the metabolism of
clozapine and acetaminophene, in the absence and presence
of trapping agents, e.g. GSH, have been reported [89, 90].
As for acetaminophene, the known oxidative metabolic
detoxification pathway could be simulated, i.e. GSH and N-
acetylcysteine adducts of the electrochemically generated
reactive acetaminophene metabolite N-acetyl-p-benzoqui-
noneimine (NAPQI) could be identified. In contrast with
in-vivo experiments, however, different isomers of these
adducts were observed [90]. In the study on clozapine only
several of the known oxidative metabolic pathways were
simulated [89].
Jurva et al. performed comprehensive studies on the
comparability of EC–MS and cytochrome P 450-catalyzed
reactions [91, 92] and found that EC–MS successfully
simulated those cytochrome P450 reactions which are
initiated by a one-electron oxidation, for example N-deal-
kylation, S-oxidation, P-oxidation, alcohol oxidation, and
dehydrogenation, whereas reactions initiated by direct
hydrogen atom abstraction, e.g. O-dealkylation or hydroxyl-
ation of unsubstituted aromatic rings, were not simulated,
because the oxidation potentials were too high for electro-
chemical oxidation in aqueous solutions. A further disad-
vantage is that EC lacks the stereospecifity of the reactions,
in contrast with cytochrome P 450-catalyzed reactions, [91].
New or improved strategies for detection of metabolites
Compared with GC, LC has always suffered from modest
separating power. One way of improving chromatographic
resolution is to reduce particle size. This results in an in-
crease in pressure, however. Upon the commercialization of
sub-two-micron particles and LC pumps which can handle
pressure up to 1000 bar, ultra-high-performance liquid chro-
matography (UHPLC) became an attractive tool for drug
metabolism studies. Johnson et al. [67] investigated the
potential of UHPLC for the study of the human metabolism
of acetaminophene. They reported improved sensitivity by
a factor of three compared with a monolithic column, and
significantly more metabolites were detected. UHPLC
reduces analysis time and the peak width becomes much
smaller than in conventional LC. When using UHPLC the
mass spectrometric detection duty cycle becomes very
important. If insufficient data points are acquired across
an LC peak, loss of chromatographic performance can be
observed. For most MS instruments the duty cycle in
single-analyzer MS is low; this can increase substantially
(typically to one second or more) in MS–MS mode,
however, especially with hybrid systems enabling accurate
mass measurement. To benefit fully from the UHPLC,
therefore, the chromatographic separation must be set up in
such a way that takes chromatographic resolution and MS
duty cycle into account.
As mentioned earlier, the MS response factor is strongly
analyte-dependent. Hydroxylation of the parent drug may
already strongly affect the signal. Radiolabeling is time-
consuming and expensive. Because most pharmaceutical
compounds contain nitrogen atoms, the chemiluminescent
nitrogen detector [93] (CLND) is an interesting approach
for quantifying metabolites without use of a reference
compound [94]. CLND furnishes molar information,
assuming calibration is performed and the number of
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nitrogen atoms is known. All nitrogen atoms present in the
molecule undergo high-temperature oxidation to form nitric
oxide (NO). The gas is mixed with ozone and excited
nitrogen dioxide NO2
 
is formed, which emits light.
Taylor et al. performed simultaneous identification, struc-
ture elucidation, and quantitation of in-vivo metabolites
using stable isotope LC–MSn and chemiluminescent detec-
tion. They found that this combination increased the speed
of acquisition of ADME/PK data without radiolabeling.
Edlung et al. [95] used CLND and LC–MS–MS to study
the metabolism of a 5HT2c agonist. They also found
excellent correlation between radioactivity detection and
the CLND. CLND is less sensitive than LC–MS, and the
real limit of quantification in biological fluids must be
further investigated. In toxicological investigation metabo-
lite reference compounds are difficult to obtain and are
often unstable. In these circumstances CLND in combina-
tion with LC–MS will enable the analyst to obtain accurate
and precise quantitative data.
Metal atoms and non-metal atoms such as Cl, Br, I, S, or
P can also be detected by inductively coupled plasma mass
spectrometry (ICP–MS) [96]. Because non-metal atoms are
often present in pharmaceutical products and because, in
principle, sensitivity is element-independent, the technique
is of interest for drug-metabolism studies. Coupling of LC
to ICP–MS is, also, a well established technique. Applica-
tions of ICP–MS have been described for metallodrugs, for
example cisplatin- and, more recently, ICP–MS in combi-
nation with ESI–MS has been used to investigate the
metabolism of 2-, 3- and 4-bromobenzoic acids in bile-
cannulated rats [97]. ICP-MS is certainly more expensive
than CLND, but in combination with ESI LC–MS–MS
these techniques may become very powerful.
During early drug development the distribution of a drug
into animal tissue is routinely investigated by whole-body
autoradiography (WBA) [98]. Because only the radioactiv-
ity is measured, a limitation of the technique is that the
parent drug and its metabolites cannot be distinguished.
This can be partially overcome by analyzing different tissue
sections by LC–MS–MS, which can be time-consuming.
Ideally one would like to analyze the tissue directly by
mass spectrometry imaging (MSI). This technique, based
on matrix-assisted laser-desorption ionization (MALDI)
MS, was originally developed for imaging of peptides and
proteins [99]; more recently it has been used for identifi-
cation of low-molecular-weight compounds [100, 101]. A
typical workflow is illustrated in Fig. 6. In such studies
radiolabled parent drug is administered to the animal.
Shortly after sacrifice the complete animal is frozen and
slices of the whole body, approximately 30–50 μm thick,
are obtained by use of a large cryomicrotome. The
radioactivity is measured and a complete image which
reflects the radioactivity within the section of the slice can
be obtained. The main challenge when using MALDI MSI
is transfer of the tissue section to the MALDI target and
deposition of the required matrix. An open question after
qualitative speciation has been demonstrated is how the
drug or the metabolites can be quantified. Signor et al.
[102] described a strategy in which they used standard
addition of a reference compound, but substantial variabil-
Fig. 6 Schematic diagram of
the imaging of whole-body
tissue sections by whole body
autoradiography and matrix-
assisted laser desorption/
ionization mass spectrometric
imaging. (Reproduced from Ref.
[101]; with permission)
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ity was encountered. Essentially, MSI could also be used to
detect the presences of drugs or their metabolites in post-
mortem samples.
Perspectives
Identification and quantification of metabolites in complex
matrices remain challenging tasks. MS is currently very
important in such investigations, but although improve-
ments in MS sensitivity and performance, for example scan
functions and scan speed, are expected in the near future,
current ionization techniques, for example MALDI or ESI,
still suffer from compound-dependent response and are
prone to matrix effects, making quantitative analysis
difficult. The pharmaceutical industry is also shifting
toward therapeutic peptides and proteins, complex thera-
peutics which will challenge the biotransformation analyst
still further. It is, however, expected that MS will remain
the instrument of choice for most of the new challenges
faced in drug metabolism [103].
A novel approach that has recently been applied is the
use of chemometric tools for the screening of drug
metabolites [104, 105]. Multivariate approaches are widely
used in “omics” to search for endogenous biomarkers.
Interestingly, it has been realized that the same tools and
samples can be used to search for exogenous and
endogenous metabolites. Sample analysis is more complex
when using this approach, however, and new sample-
preparation strategies must be established to maximize the
effect of such software-based techniques. De-novo tools or
databases for automated interpretation of spectra must also
be developed for precise identification of the metabolites
present. Such novel software in combination with MS or
other techniques will prove a powerful combination in
solving future metabolite biotransformation problems.
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